Just posted some highlights. For Suraj's benefit, no, the world doesn't come to an end in 2015 Suraj despite your concerns in your last note. MDXG is not ramping up its sales force because they expect sales to drop off the face of the earth starting 1/1/2015...quite the contrary..they expect continued significant growth. Also, despite shorties (Streetsweeper and affiliated hedge funds) attack on management, CH has it right in highlighting MDXG's "superior management team" as justifying a premium valuation. Also of note for shorty and Suraj is the "competitive moat" reference. Suraj believes docs don't know the difference between Epifix and the would be competitors. That is simply laughable. Had Suraj done any homework whatsoever other than doing the bidding of others, (i.e. had he surveyed docs who had used Epifix and others) he would not have been able to write such drivel. Only difference I have with CH is the price target. They are using 6.5X 2015 revenue. First, I think the multiple should be higher due to Amniofix. Second, they are using $146 million for revenue for 2015 which I think will prove to be quite conservative...but I understand why they are being conservative. My 12 month target is actually closer to $15.